Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16151062 | 0.85 | LMNA (0.46) | MEN1KMT2ALMNATSHRHTT | |
| SCHEMBL3396285 | 0.82 | LMNA (0.44) | MEN1KMT2ALMNATSHRHTT | |
| SCHEMBL3396292 | 0.82 | LMNA (0.44) | MEN1KMT2ALMNATSHRHTT | |
| SCHEMBL28506200 | 0.81 | POLB (0.50) | MEN1KMT2APOLBHRH4HRH3 | |
| SCHEMBL2931560 | 0.80 | TSHR (0.54) | KMT2APOLBLMNATSHRHTT | |
| SCHEMBL1447852 | 0.80 | CPS1 (0.56) | MEN1KMT2APOLBHRH4HRH3 | |
| SCHEMBL18390530 | 0.79 | LMNA (0.71) | MEN1KMT2APOLBHRH4LMNA | |
| SCHEMBL16155915 | 0.79 | MEN1 (0.47) | MEN1KMT2APOLBLMNA | |
| SCHEMBL31403224 | 0.78 | KMT2A (0.55) | MEN1KMT2APOLBHRH4HRH3 | |
| SCHEMBL24381981 | 0.76 | KDM4E (0.47) | MEN1KMT2APOLBHRH4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| EP-2247591-A1 | PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | MEN1 246/4885KMT2A 1885/4885POLB 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.